NurrOn Pharmaceuticals Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $1M

  • Investors
  • 2

NurrOn Pharmaceuticals General Information

Description

Developer of disease-modifying Parkinson's Therapies dedicated to developing novel targeted therapeutics for the treatment of Nurr1-related incurable human disorders. The company is discovering and developing substances that have a mechanism to relieve symptoms of Parkinson's disease by protecting the dopaminergic neurons, helping PD patients improve clinical outcomes.

Contact Information

Website
www.nurronpharma.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 299 Lexington Street
  • Suite 112
  • Woburn, MA 01801
  • United States
Primary Industry
Pharmaceuticals
Vertical(s)
HealthTech
Corporate Office
  • 299 Lexington Street
  • Suite 112
  • Woburn, MA 01801
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NurrOn Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 30-Jul-2021 $1M Completed Pre-Clinical Trials
To view NurrOn Pharmaceuticals’s complete valuation and funding history, request access »

NurrOn Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of disease-modifying Parkinson's Therapies dedicated to developing novel targeted therapeutics for the treatme
Pharmaceuticals
Woburn, MA

San Diego, CA
 

Wellesley Hills, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NurrOn Pharmaceuticals Competitors (3)

One of NurrOn Pharmaceuticals’s 3 competitors is Autobahn Therapeutics, a Venture Capital-Backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Autobahn Therapeutics Venture Capital-Backed San Diego, CA
Climb Bio Formerly VC-backed Wellesley Hills, MA
Neuropore Therapies Corporation San Diego, CA
You’re viewing 3 of 3 competitors. Get the full list »

NurrOn Pharmaceuticals Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Daewoong Pharmaceutical Company Corporation Minority
Hanall Biopharma Company Corporation Minority
To view NurrOn Pharmaceuticals’s complete investors history, request access »

Ready to get started?

Request a free trial

NurrOn Pharmaceuticals FAQs

  • When was NurrOn Pharmaceuticals founded?

    NurrOn Pharmaceuticals was founded in 2020.

  • Where is NurrOn Pharmaceuticals headquartered?

    NurrOn Pharmaceuticals is headquartered in Woburn, MA.

  • What industry is NurrOn Pharmaceuticals in?

    NurrOn Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is NurrOn Pharmaceuticals a private or public company?

    NurrOn Pharmaceuticals is a Private company.

  • What is NurrOn Pharmaceuticals’s current revenue?

    The current revenue for NurrOn Pharmaceuticals is .

  • How much funding has NurrOn Pharmaceuticals raised over time?

    NurrOn Pharmaceuticals has raised $1M.

  • Who are NurrOn Pharmaceuticals’s investors?

    Daewoong Pharmaceutical Company and Hanall Biopharma Company have invested in NurrOn Pharmaceuticals.

  • Who are NurrOn Pharmaceuticals’s competitors?

    Autobahn Therapeutics, Climb Bio, and Neuropore Therapies are competitors of NurrOn Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »